Brouwer Mèdea, Offermans Mandy, van Nuil Lisanne, Poukens Astrid, van Oijen Brigit, Dormans Tom
Department of Pharmacology, Zuyderland MC, Heerlen, The Netherlands.
Department of Intensive Care, Zuyderland MC, Heerlen, The Netherlands.
Eur J Case Rep Intern Med. 2024 Sep 3;11(9):004784. doi: 10.12890/2024_004784. eCollection 2024.
The prevalence of type 2 diabetes mellitus has surged globally. Metformin is recommended as the first-line oral treatment. However, metformin-associated lactic acidosis (MALA) is recognized as a rare but potentially dangerous complication. The pathogenesis of MALA is multifactorial, primarily resulting from the interference of metformin with mitochondrial function and hepatic gluconeogenesis, leading to lactate accumulation. Risk of MALA escalates with impaired kidney function, poorly controlled diabetes, fasting, and liver dysfunction.
A 57-year-old woman with diabetes and hypertension presented with prolonged gastrointestinal symptoms. During this episode she continued using metformin. She had severe metabolic acidosis and acute kidney injury. Continuous venovenous hemodiafiltration was initiated, resulting in significant clinical improvement and normalized arterial blood gas parameters within 16 hours.
The pharmacokinetic properties of metformin facilitate efficient elimination via hemodialysis and/or hemofiltration. Continuous venovenous hemodiafiltration emerges as effective for MALA treatment. In the case described the calculated metformin clearance during continuous venovenous hemodiafiltration was notably higher than reported values, possibly due to residual renal clearance. Clinical improvement occurred despite elevated metformin levels, suggesting a lack of correlation between metformin levels and patient outcomes. Comorbidities rather than metformin levels guide treatment decisions in MALA.
This case underscores the efficacy of continuous venovenous hemodiafiltration in the treatment of MALA, suggesting its potential as a standard therapeutic approach. However, further research is needed to elucidate the complex interplay between metformin levels, clinical presentation, (extracorporeal) treatment modalities and outcome in MALA.
Continuous venovenous hemodiafiltration seems to be an efficient and effective treatment to eliminate metformin in patients with metformin-associated lactic acidosis.The metformin level does not seem to correlate with the clinical condition of the patient.For a comparison between the effectiveness of different renal replacement therapies in metformin-associated lactic acidosis, more research is needed.
2型糖尿病在全球的患病率激增。二甲双胍被推荐作为一线口服治疗药物。然而,二甲双胍相关乳酸酸中毒(MALA)被认为是一种罕见但潜在危险的并发症。MALA的发病机制是多因素的,主要是由于二甲双胍干扰线粒体功能和肝糖异生,导致乳酸积累。肾功能受损、糖尿病控制不佳、禁食和肝功能障碍会使MALA的风险升高。
一名患有糖尿病和高血压的57岁女性出现了持续的胃肠道症状。在此期间她继续服用二甲双胍。她出现了严重的代谢性酸中毒和急性肾损伤。开始进行持续静静脉血液透析滤过,16小时内临床症状显著改善,动脉血气参数恢复正常。
二甲双胍的药代动力学特性有利于通过血液透析和/或血液滤过有效清除。持续静静脉血液透析滤过被证明对MALA治疗有效。在所述病例中,持续静静脉血液透析滤过期间计算出的二甲双胍清除率明显高于报告值,可能是由于残余肾清除率。尽管二甲双胍水平升高,但临床症状仍有改善,这表明二甲双胍水平与患者预后之间缺乏相关性。在MALA中,合并症而非二甲双胍水平指导治疗决策。
该病例强调了持续静静脉血液透析滤过在治疗MALA中的有效性,表明其作为标准治疗方法的潜力。然而,需要进一步研究以阐明二甲双胍水平、临床表现、(体外)治疗方式和MALA预后之间的复杂相互作用。
持续静静脉血液透析滤过似乎是清除二甲双胍相关乳酸酸中毒患者体内二甲双胍的一种高效且有效的治疗方法。二甲双胍水平似乎与患者的临床状况无关。对于比较不同肾脏替代疗法在二甲双胍相关乳酸酸中毒中的有效性,还需要更多研究。